PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.

1. Comparative Detection Performance of PSMA and Non-PSMA PET Tracers in Recurrent and Primary Prostate Cancer: A Systematic Review and Network Meta-Analysis.Clinical nuclear medicine · 2026
   Pooled it
2. The Impact of Positron Emission Tomography with 18F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial.The Journal of urology · 2019
   Trial
3. The Prevalence and Significance of Incidental Positron Emission Tomography Findings in the Brain Using Radiotracers Other than [Diagnostics (Basel, Switzerland) · 2025
   Review
4. Role ofMolecular imaging and radionuclide therapy · 2024
   Article
5. Diagnostic accuracy of F-18-Fluorocholine PET/CT and multiparametric MRI for prostate cancer.Prostate international · 2022
   Article
6. Multiple metabolic pathways fuel the truncated tricarboxylic acid cycle of the prostate to sustain constant citrate production and secretion.Molecular metabolism · 2022
   Article
7. Positron emission tomography molecular imaging-based cancer phenotyping.Cancer · 2022
   Review
8. Beyond the Prognostic Value of 2-[Diagnostics (Basel, Switzerland) · 2022
   Review
9. Prostate Cancer Diagnostic Algorithm as a "Road Map" from the First Stratification of the Patient to the Final Treatment Decision.Life (Basel, Switzerland) · 2021
   Article
10. WillEndocrine · 2021
    Review
11. The Evolving Role ofFrontiers in oncology · 2021
    Article
12. Nodal recurrence patterns on PET/CT after RTOG-based nodal radiotherapy for prostate cancer.Clinical and translational radiation oncology · 2020
    Article
13. Characteristics, trend, and methodological quality of systematic reviews and meta-analyses in nuclear medicine: A bibliometric analysis of studies published between 2005 and 2016.Medicine · 2019
    Article
14. European journal of nuclear medicine and molecular imaging · 2019
    Article
15. Impact of penalizing factor in a block-sequential regularized expectation maximization reconstruction algorithm forEJNMMI physics · 2019
    Article
16. Radiolabelled choline versus PSMA PET/CT in prostate cancer restaging: a meta-analysis.American journal of nuclear medicine and molecular imaging · 2019
    Article
17. La Radiologia medica · 2018
    Review
18. Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis.European journal of nuclear medicine and molecular imaging · 2018
    Article
19. Update onJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2018
    Review
20. Current status of theranostics in prostate cancer.European journal of nuclear medicine and molecular imaging · 2018
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

5 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as